Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Synthesis and Anticancer Activity of Novel Indole Derivatives as Dual EGFR/SRC Kinase Inhibitors

Author(s): Sureyya Olgen*, Sevde Nur Biltekin Kaleli, Banu Taktak Karaca, Ural U. Demirel and Hacer Karatas Bristow

Volume 31, Issue 24, 2024

Published on: 31 July, 2023

Page: [3798 - 3817] Pages: 20

DOI: 10.2174/0929867330666230626143911

Price: $65

Abstract

Background: Recent studies showed that the cooperation between c-SRC and EGFR is responsible for more aggressive phenotype in diverse tumors, including glioblastomas and carcinomas of the colon, breast, and lung. Studies show that combination of SRC and EGFR inhibitors can induce apoptosis and delay the acquired resistance to chemotherapy. Therefore, such combination may lead to a new therapeutic strategy for the treatment of EGFR-mutant lung cancer. Osimertinib was developed as a third-generation EGFR-TKI to combat the toxicity of EGFR mutant inhibitors. Due to the resistance and adverse reaction of osimertinib and other kinase inhibitors, 12 novel compounds structurally similar to osimertinib were designed and synthesized.

Methods: Compounds were synthesized by developing novel original synthesis methods and receptor interactions were evaluated through a molecular docking study. To evaluate their inhibitory activities against EGFR and SRC kinase, in vitro enzyme assays were used. Anticancer potencies were determined using lung, breast, prostate (A549, MCF6, PC3) cancer cell lines. Compounds were also tested against normal (HEK293) cell line to evaluate their cyctotoxic effects.

Results: Although, none of compounds showed stronger inhibition compared to osimertinib in the EGFR enzyme inhibition studies, compound 16 showed the highest efficacy with an IC50 of 1.026 μM. It also presented potent activity against SRC kinase with an IC50 of 0.002 μM. Among the tested compounds, the urea containing derivatives 6-11 exhibited a strong inhibition profile (80.12-89.68%) against SRC kinase in comparison to the reference compound dasatinib (93.26%). Most of the compounds caused more than 50% of cell death in breast, lung and prostate cancer cell lines and weak toxicity for normal cells in comparison to reference compounds osimertinib, dasatinib and cisplatin. Compound 16 showed strong cytotoxicity on lung and prostate cancer cells. Treatment of prostate cancer cell lines with the most active compound, 16, significantly increased the caspase-3 (8-fold), caspase-8 (6-fold) and Bax (5.7-fold) levels and decreased the Bcl-2 level (2.3-fold) compared to the control group. These findings revealed that the compound 16 strongly induces apoptosis in the prostate cancer cell lines.

Conclusion: Overall kinase inhibition, cytotoxicity and apoptosis assays presented that compound 16 has dual inhibitory activity against SRC and EGFR kinases while maintaining low toxicity against normal cells. Other compounds also showed considerable activity profiles in kinase and cell culture assays.

« Previous Next »
[1]
Olgen, S. Overview on anticancer drug design and development. Curr. Med. Chem., 2018, 25(15), 1704-1719.
[http://dx.doi.org/10.2174/0929867325666171129215610] [PMID: 29189124]
[2]
Pancewicz-Wojtkiewicz, J.; Bernatowicz, P.L. The effect of afatinib tratment in non-small cell lung cancer cells. Anticancer Res., 2017, 37(7), 3543-3546.
[http://dx.doi.org/10.21873/anticanres.11723] [PMID: 28668844]
[3]
Bedi, S.; Khan, S.A.; AbuKhader, M.M.; Alam, P.; Siddiqui, N.A.; Husain, A. A comprehensive review on Brigatinib – A wonder drug for targeted cancer therapy in non-small cell lung cancer. Saudi Pharm. J., 2018, 26(6), 755-763.
[http://dx.doi.org/10.1016/j.jsps.2018.04.010] [PMID: 30202213]
[4]
Arora, A.; Scholar, E.M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther., 2005, 315(3), 971-979.
[http://dx.doi.org/10.1124/jpet.105.084145] [PMID: 16002463]
[5]
Traxler, P.; Furet, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther., 1999, 82(2-3), 195-206.
[http://dx.doi.org/10.1016/S0163-7258(98)00044-8] [PMID: 10454197]
[6]
Zhang, J.; Yang, P.L.; Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer, 2009, 9(1), 28-39.
[http://dx.doi.org/10.1038/nrc2559] [PMID: 19104514]
[7]
Olgen, S. Design strategies, structures and molecular interacions of small molecule Src inhibitors. Anticancer. Agents Med. Chem., 2016, 16(8), 992-1002.
[http://dx.doi.org/10.2174/1871520616666160223111800] [PMID: 26902603]
[8]
Ramalingam, S.S.; Jänne, P.A.; Mok, T.; O’Byrne, K.; Boyer, M.J.; Von Pawel, J.; Pluzanski, A.; Shtivelband, M.; Docampo, L.I.; Bennouna, J.; Zhang, H.; Liang, J.Q.; Doherty, J.P.; Taylor, I.; Mather, C.B.; Goldberg, Z.; O’Connell, J.; Paz-Ares, L. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): A randomised, double-blind, phase 3 trial. Lancet Oncol., 2014, 15(12), 1369-1378.
[http://dx.doi.org/10.1016/S1470-2045(14)70452-8] [PMID: 25439691]
[9]
Metibemu, D.S.; Akinloye, O.A.; Akamo, A.J.; Ojo, D.A.; Okeowo, O.T.; Omotuyi, I.O. Exploring receptor tyrosine kinases-inhibitors in cancer treatments. Egypt. J. Med. Hum. Genet., 2019, 20(1), 35.
[http://dx.doi.org/10.1186/s43042-019-0035-0]
[10]
Waring, M.J. The discovery of osimertinib (Tagrisso): An irreversible inhibitor of activating and T790M resistant forms of the epidermal growth factor receptor tyrosine kinase for the treatment of non-small cell lung cancer. In: Successful Drug Discover; , 2018; 3, pp. 341-357.
[http://dx.doi.org/10.1002/9783527808694.ch12]
[11]
Yan, X.E.; Ayaz, P.; Zhu, S.J.; Zhao, P.; Liang, L.; Zhang, C.H.; Wu, Y.C.; Li, J.L.; Choi, H.G.; Huang, X.; Shan, Y.; Shaw, D.E.; Yun, C.H. Structural basis of AZD9291 selectivity for EGFR T790M. J. Med. Chem., 2020, 63(15), 8502-8511.
[http://dx.doi.org/10.1021/acs.jmedchem.0c00891] [PMID: 32672461]
[12]
Butterworth, S.; Cross, D.A.E.; Finlay, M.R.V.; Ward, R.A.; Waring, M.J. The structure-guided discovery of osimertinib: The first U.S. FDA approved mutant selective inhibitor of EGFR T790M. MedChemComm, 2017, 8(5), 820-822.
[http://dx.doi.org/10.1039/C7MD90012K] [PMID: 30108799]
[13]
An, B.; Pan, T.; Hu, J.; Pang, Y.; Huang, L.; Chan, A.S.C.; Li, X.; Yan, J. The discovery of a potent and selective third-generation EGFR kinase inhibitor as a therapy for EGFR L858R/T790M double mutant non-small cell lung cancer. Eur. J. Med. Chem., 2019, 183, 111709-111729.
[http://dx.doi.org/10.1016/j.ejmech.2019.111709] [PMID: 31581004]
[14]
Ishizawar, R.; Parsons, S.J. c-Src and cooperating partners in human cancer. Cancer Cell, 2004, 6(3), 209-214.
[http://dx.doi.org/10.1016/j.ccr.2004.09.001] [PMID: 15380511]
[15]
Belli, S.; Esposito, D.; Servetto, A.; Pesapane, A.; Formisano, L.; Bianco, R. c-Src and EGFR inhibition in molecular cancer therapy: What else can we improve? Cancers, 2020, 12(6), 1489.
[http://dx.doi.org/10.3390/cancers12061489.] [PMID: 32517369]
[16]
Ichihara, E.; Westover, D.; Meador, C.B.; Yan, Y.; Bauer, J.A.; Lu, P.; Ye, F.; Kulick, A.; de Stanchina, E.; McEwen, R.; Ladanyi, M.; Cross, D.; Pao, W.; Lovly, C.M. SFK/FAK signaling attenuates osimertinib efficacy in both drug- sensitive and drug-resistant models of EGFR-mutant lung cancer. Cancer Res., 2017, 77(11), 2990-3000.
[http://dx.doi.org/10.1158/0008-5472.CAN-16-2300] [PMID: 28416483]
[17]
Ghosh, A.K.; Brindisi, M. Urea derivatives in modern drug discovery and medicinal chemistry. J Med Chem., 2020, 63(6), 2751-2788.
[http://dx.doi.org/10.1021/acs.jmedchem.9b01541] [PMID: 31789518]
[18]
Sahin, Z.; Biltekin, S.N.; Yurttas, L.; Berk, B.; Özhan, Y.; Sipahi, H.; Gao, Z.G.; Jacobson, K.A.; Demirayak, Ş. Novel cyanothiouracil and cyanothiocytosine derivatives as concentration-dependent selective inhibitors of U87MG glioblastomas: Adenosine receptor binding and potent PDE4 inhibition. Eur. J. Med. Chem., 2021, 212, 113125.
[http://dx.doi.org/10.1016/j.ejmech.2020.113125] [PMID: 33422981]
[19]
Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods, 1983, 65(1-2), 55-63.
[http://dx.doi.org/10.1016/0022-1759(83)90303-4] [PMID: 6606682]
[20]
Gong, L.; Tang, Y.; An, R.; Lin, M.; Chen, L.; Du, J. RTN1-C mediates cerebral ischemia/reperfusion injury via ER stress and mitochondria-associated apoptosis pathways. Cell Death Dis., 2017, 8(10), e3080.
[http://dx.doi.org/10.1038/cddis.2017.465] [PMID: 28981095]
[21]
El-Dash, Y.; Elzayat, E.; Abdou, A.M.; Hassan, R.A. Novel thienopyrimidine-aminothiazole hybrids: Design, synthesis, antimicrobial screening, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and VEGFR-2 inhibition. Bioorg. Chem., 2021, 114, 105137.
[http://dx.doi.org/10.1016/j.bioorg.2021.105137] [PMID: 34237644]
[22]
Lambuk, L.; Iezhitsa, I.; Agarwal, R.; Bakar, N.S.; Agarwal, P.; Ismail, N.M. Antiapoptotic effect of taurine against NMDA-induced retinal excitotoxicity in rats. Neurotoxicology, 2019, 70, 62-71.
[http://dx.doi.org/10.1016/j.neuro.2018.10.009] [PMID: 30385388]
[23]
Donepudi, M.; Sweeney, A.M.; Briand, C.; Grütter, M.G. Insights into the regulatory mechanism for caspase-8 activation. Mol. Cell, 2003, 11(2), 543-549.
[http://dx.doi.org/10.1016/S1097-2765(03)00059-5] [PMID: 12620240]
[24]
Dolka, I.; Król, M.; Sapierzyński, R. Evaluation of apoptosis-associated protein (Bcl-2, Bax, cleaved caspase-3 and p53) expression in canine mammary tumors: An immunohistochemical and prognostic study. Res. Vet. Sci., 2016, 105, 124-133.
[http://dx.doi.org/10.1016/j.rvsc.2016.02.004] [PMID: 27033920]
[25]
Cheng, C.; Wen, S.; Li, H.J. Fluorine- and/or deuterium-containing compounds for treating non-small cell lung cancer and related diseases. US Patent 2019/0169171 Al,, 2019.
[26]
Jiang, Y.P. Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof. EP Patent 3 216 786 A1,, 2017.
[27]
Alves, J.; Goueli, S.A.; Zegzouti, H. www.promega.com/tbs/tm313/tm313.html.
[28]
Fritsch, M.; Günther, S.D.; Schwarzer, R.; Albert, M.C.; Schorn, F.; Werthenbach, J.P.; Schiffmann, L.M.; Stair, N.; Stocks, H.; Seeger, J.M.; Lamkanfi, M.; Krönke, M.; Pasparakis, M.; Kashkar, H. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature, 2019, 575(7784), 683-687.
[http://dx.doi.org/10.1038/s41586-019-1770-6] [PMID: 31748744]
[29]
Ma, C.; MacKenzie, S.H.; Clay Clark, A. Redesigning the procaspase-8 dimer interface for improved dimerization. Protein Sci., 2014, 23(4), 442-453.
[http://dx.doi.org/10.1002/pro.2426] [PMID: 24442640]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy